JP2022547505A5 - - Google Patents

Info

Publication number
JP2022547505A5
JP2022547505A5 JP2022514833A JP2022514833A JP2022547505A5 JP 2022547505 A5 JP2022547505 A5 JP 2022547505A5 JP 2022514833 A JP2022514833 A JP 2022514833A JP 2022514833 A JP2022514833 A JP 2022514833A JP 2022547505 A5 JP2022547505 A5 JP 2022547505A5
Authority
JP
Japan
Prior art keywords
factor
mhc
cells
immunotolerogenic
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022514833A
Other languages
English (en)
Japanese (ja)
Other versions
JP7753197B2 (ja
JP2022547505A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/058281 external-priority patent/WO2021044379A1/en
Publication of JP2022547505A publication Critical patent/JP2022547505A/ja
Publication of JP2022547505A5 publication Critical patent/JP2022547505A5/ja
Priority to JP2025117434A priority Critical patent/JP2025170191A/ja
Application granted granted Critical
Publication of JP7753197B2 publication Critical patent/JP7753197B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022514833A 2019-09-05 2020-09-04 ユニバーサルドナー細胞 Active JP7753197B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025117434A JP2025170191A (ja) 2019-09-05 2025-07-11 ユニバーサルドナー細胞

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962896473P 2019-09-05 2019-09-05
US62/896,473 2019-09-05
US202062979771P 2020-02-21 2020-02-21
US62/979,771 2020-02-21
PCT/IB2020/058281 WO2021044379A1 (en) 2019-09-05 2020-09-04 Universal donor cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025117434A Division JP2025170191A (ja) 2019-09-05 2025-07-11 ユニバーサルドナー細胞

Publications (3)

Publication Number Publication Date
JP2022547505A JP2022547505A (ja) 2022-11-14
JP2022547505A5 true JP2022547505A5 (https=) 2023-09-11
JP7753197B2 JP7753197B2 (ja) 2025-10-14

Family

ID=72473593

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022514833A Active JP7753197B2 (ja) 2019-09-05 2020-09-04 ユニバーサルドナー細胞
JP2025117434A Pending JP2025170191A (ja) 2019-09-05 2025-07-11 ユニバーサルドナー細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025117434A Pending JP2025170191A (ja) 2019-09-05 2025-07-11 ユニバーサルドナー細胞

Country Status (13)

Country Link
US (5) US11104918B2 (https=)
EP (1) EP4025690A1 (https=)
JP (2) JP7753197B2 (https=)
KR (1) KR20220052370A (https=)
CN (1) CN114375300A (https=)
AU (1) AU2020341186A1 (https=)
BR (1) BR112022004026A2 (https=)
CA (1) CA3150235A1 (https=)
CO (1) CO2022002586A2 (https=)
IL (1) IL291044A (https=)
MX (1) MX2022002783A (https=)
PH (1) PH12022550543A1 (https=)
WO (1) WO2021044379A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
PH12022550542A1 (en) 2019-09-05 2023-03-20 Crispr Therapeutics Ag Universal donor cells
CA3150235A1 (en) * 2019-09-05 2021-03-11 Alireza Rezania Universal donor cells
WO2022144855A1 (en) 2020-12-31 2022-07-07 Crispr Therapeutics Ag Universal donor cells
US20240226164A1 (en) * 2021-05-27 2024-07-11 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
WO2023183313A1 (en) * 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
CN116732099B (zh) * 2023-08-07 2023-11-24 北赛泓升(北京)生物科技有限公司 一种干细胞多重CRISPR/Cas基因组编辑方法
WO2025202874A1 (en) 2024-03-25 2025-10-02 Crispr Therapeutics Ag Genetically modified cells expressing glp-1 receptor agonist
WO2026069163A1 (en) 2024-09-25 2026-04-02 Crispr Therapeutics Ag Differentiation method for producing immature beta cells

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5283058A (en) 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US7056502B2 (en) 2000-04-28 2006-06-06 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
US20060222633A1 (en) 2000-05-11 2006-10-05 Yale University Prevention, decrease, and/or treatment of immunoreactivity by depleting and/or inactivating antigen presenting cells in the host
WO2003014313A2 (en) 2001-08-06 2003-02-20 Bresagen, Ltd. Alternative compositions and methods for the culture of stem cells
US20050266554A1 (en) 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
CN103898047B (zh) 2003-12-23 2020-03-03 维亚希特公司 定形内胚层
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
US7541185B2 (en) 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
US8586357B2 (en) 2003-12-23 2013-11-19 Viacyte, Inc. Markers of definitive endoderm
US8187878B2 (en) 2004-08-13 2012-05-29 University Of Georgia Research Foundation, Inc. Methods for increasing definitive endoderm differentiation of pluripotent human embryonic stem cells with PI-3 kinase inhibitors
US8999944B2 (en) 2005-01-20 2015-04-07 University Of Rochester Thioredoxin interacting protein (TXNIP) as regulator of vascular function
WO2007051038A2 (en) 2005-10-27 2007-05-03 Cythera, Inc. Pdx1-expressing dorsal and ventral foregut endoderm
SG170021A1 (en) 2006-02-23 2011-04-29 Novocell Inc Compositions and methods useful for culturing differentiable cells
JP6110048B2 (ja) 2006-03-02 2017-04-05 ヴィアサイト,インコーポレイテッド 内分泌前駆細胞、膵臓ホルモン発現細胞及びそれらの製造方法
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
US7964402B2 (en) 2006-05-25 2011-06-21 Sanford-Burnham Medical Research Institute Methods for culture and production of single cell populations of human embryonic stem cells
DK2185693T3 (da) 2007-07-31 2019-09-23 Lifescan Inc Differentiering af humane embryoniske stamceller
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US8623650B2 (en) 2007-10-19 2014-01-07 Viacyte, Inc. Methods and compositions for feeder-free pluripotent stem cell media containing human serum
CA2954431C (en) 2007-11-27 2021-08-24 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic cells
US8338170B2 (en) 2008-04-21 2012-12-25 Viacyte, Inc. Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
US7939322B2 (en) 2008-04-24 2011-05-10 Centocor Ortho Biotech Inc. Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm
US20120058105A1 (en) 2008-06-27 2012-03-08 Martin Kean Chong Ng Method of treatment of vascular complications
US9234178B2 (en) 2008-10-31 2016-01-12 Janssen Biotech, Inc. Differentiation of human pluripotent stem cells
EP2350265B1 (en) 2008-10-31 2019-04-17 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
US8895300B2 (en) 2008-11-04 2014-11-25 Viacyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
US8008075B2 (en) 2008-11-04 2011-08-30 Viacyte, Inc. Stem cell aggregate suspension compositions and methods of differentiation thereof
JP2012508584A (ja) 2008-11-14 2012-04-12 ヴィアサイト,インコーポレイテッド ヒト多能性幹細胞由来膵臓細胞のカプセル化
US20100272710A1 (en) * 2009-03-26 2010-10-28 Abdelhadi Rebbaa Compositions and methods for treating and preventing aging-associated diseases
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
EP2421957B1 (en) 2009-04-22 2020-11-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
CN107603943B (zh) 2009-04-27 2019-10-11 威盛细胞有限公司 支持多能细胞生长的小分子和其方法
CN103952372B (zh) 2009-07-20 2016-10-05 詹森生物科技公司 人胚胎干细胞的分化
US8785184B2 (en) 2009-07-20 2014-07-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
SG10201408552YA (en) 2009-12-23 2015-02-27 Janssen Biotech Inc Differentiation of human embryonic stem cells
CN102712902B (zh) 2009-12-23 2019-01-08 詹森生物科技公司 人胚胎干细胞的分化
PL2853589T3 (pl) 2010-08-31 2018-05-30 Janssen Biotech, Inc Różnicowanie ludzkich zarodkowych komórek macierzystych
CN103154237B (zh) 2010-08-31 2016-03-16 詹森生物科技公司 多能干细胞的分化
ES2690663T3 (es) 2010-12-08 2018-11-21 Viacyte, Inc. Agentes y métodos para inhibir el crecimiento de células madre pluripotentes humanas
CA3205636A1 (en) 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
FI2794857T3 (fi) 2011-12-22 2026-03-25 Janssen Biotech Inc Ihmisen alkion kantasolujen erilaistaminen yksittäisiksi hormonaalisiksi insuliinipositiivisiksi soluiksi
ES2615346T3 (es) * 2012-04-25 2017-06-06 Deutsches Krebsforschungszentrum Inhibidores de la proteína que interacciona con tiorredoxina (TXNIP) para terapia
BR112014027783A2 (pt) 2012-05-07 2017-06-27 Janssen Biotech Inc diferenciação de células-tronco embrionárias humanas em endoderma pancreático
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
EP3450544A1 (en) 2012-06-08 2019-03-06 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endodrine cells
EP2861723A4 (en) 2012-06-14 2016-01-20 Janssen Biotech Inc DIFFERENTIATION OF HUMAN EMBRYONAL STEM CELLS IN ENDOCRINE PANCREAS CELLS
IL239344B2 (en) 2012-12-12 2024-06-01 Broad Inst Inc Systems engineering, methods and optimal guiding components for sequence manipulation
ES2837763T3 (es) 2012-12-31 2021-07-01 Janssen Biotech Inc Cultivo de células madre embrionarias humanas en la interconexión aire-líquido para la diferenciación en células endocrinas pancreáticas
DK2938723T3 (da) 2012-12-31 2023-02-20 Janssen Biotech Inc Differentiering af humane embryonale stamceller til pancreatiske endokrine celler under anvendelse af hb9-regulatorer
BR112015015714A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc suspensão e aglomeração de células pluripotentes humanas para diferenciação em célu-las endócrinas pancreáticas
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US9101597B2 (en) * 2013-03-14 2015-08-11 The Administration Of The Tulane Educational Fund Immunoprotective primary mesenchymal stem cells and methods
CN120796168A (zh) 2013-06-11 2025-10-17 哈佛学院校长同事会 SC-β细胞以及用于产生其的组合物和方法
KR20140144964A (ko) 2013-06-12 2014-12-22 한국생명공학연구원 티오레독신-결합 단백질을 유효성분으로 포함하는 약학적 조성물 및 이의 용도
MX374532B (es) * 2013-06-17 2025-03-06 Broad Inst Inc Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos.
WO2015065524A2 (en) 2013-11-01 2015-05-07 Janssen Biotech, Inc. Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
JP6681837B2 (ja) * 2014-03-11 2020-04-15 セレクティスCellectis 同種移植に適合するt細胞を作製するための方法
WO2015175307A1 (en) 2014-05-16 2015-11-19 Janssen Biotech, Inc. Use of small molecules to enhance mafa expression in pancreatic endocrine cells
EP3234109A4 (en) 2014-12-19 2018-06-27 Janssen Biotech, Inc. Suspension culturing of pluripotent stem cells
CN107921148A (zh) * 2015-05-08 2018-04-17 哈佛学院校长同事会 通用供体干细胞和相关方法
KR20250141836A (ko) 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
US9982267B2 (en) 2016-10-12 2018-05-29 Feldan Bio Inc. Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
CA3042495A1 (en) 2016-11-10 2018-05-17 Viacyte, Inc. Pdx1 pancreatic endoderm cells in cell delivery devices and methods thereof
JP2020505025A (ja) 2017-01-13 2020-02-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫工学的な改変をした多能性細胞
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
KR20200075851A (ko) 2017-10-19 2020-06-26 셀렉티스 개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합
US20190223416A1 (en) 2018-01-23 2019-07-25 Cotyledon, LLC Canine genome editing
WO2019160077A1 (ja) * 2018-02-16 2019-08-22 国立大学法人京都大学 低抗原性細胞の製造方法
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
CA3150235A1 (en) 2019-09-05 2021-03-11 Alireza Rezania Universal donor cells
PH12022550542A1 (en) 2019-09-05 2023-03-20 Crispr Therapeutics Ag Universal donor cells

Similar Documents

Publication Publication Date Title
JP2022547505A5 (https=)
JP7590015B2 (ja) 低抗原性細胞の製造方法
US12427170B2 (en) Universal donor cells
US20230073515A1 (en) Universal donor cells
CN106459918A (zh) 施加诱导多能干细胞产生过继细胞疗法产品
KR20220095223A (ko) 조작된 조절 t 세포 생성
KR20230093044A (ko) 인간 만능 줄기 세포로부터의 cd4+ 이펙터 및 조절 t 세포의 생성
US20220279767A1 (en) Transgenic swine, methods of making and uses thereof, and methods of making human immune system mice
US20260125655A1 (en) Method for producing low-antigenic cell
EP4112720A1 (en) Genetically modified megakaryocyte, modified platelet, and methods respectively for producing said genetically modified megakaryocyte and said modified platelet
KR20260032524A (ko) 저면역원성의 범용성 유도만능줄기세포
KR20230170442A (ko) 내인성 항원 제시 기전을 이용한 저면역원성 줄기세포 및 이의 제조 방법